Skip to main content
KAINOS MEDICINE, INC. logo

KAINOS MEDICINE, INC. — Investor Relations & Filings

Ticker · 284620 ISIN · KR7284620002 KO Professional, scientific and technical activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2026-06-16 Board/Management Inform…
Country KR South Korea
Listing KO 284620

About KAINOS MEDICINE, INC.

http://kainosmedicine.com

Kainos Medicine, Inc. is a clinical-stage research and development company specializing in the discovery of novel small molecule therapeutics. The company's primary focus is on addressing unmet medical needs in neurodegenerative disorders, infectious diseases, and oncology. Its drug pipeline includes candidates for the treatment of conditions such as Parkinson's disease, Multiple System Atrophy (MSA), AIDS, and various cancers. Kainos Medicine is dedicated to developing innovative treatments for these challenging diseases.

Recent filings

Filing Released Lang Actions
본점소재지변경
Board/Management Information Classification · 95% confidence The document text shows a change in the company's head office address. It mentions the previous and new addresses, the reason for change, the effective date of the move, and the date of the board resolution approving this change. There are no financial statements, performance data, or other reporting materials. The primary content is about a corporate facility relocation, which is an operational update but related to company management or board-level decisions. However, the change of head office location is typically considered a management or board announcement rather than a financial report or regulatory filing. Given the specific mention of board resolution and the nature of the announcement, this fits best under Board/Management Information (MANG). The document is 542 characters long, so it is unlikely to be a report publication announcement (RPA) or regulatory filing (RNS). Therefore, the classification is Board/Management Information (MANG).
2026-06-16 Korean
[기재정정]단일판매ㆍ공급계약해지
Regulatory Filings Classification · 55% confidence The document is a Korean regulatory disclosure of a correction (“정정신고”) concerning the termination of a single sales and supply contract (단일판매·공급계약해지). It does not contain financial statements or constitute an annual/quarterly report, audit report, earnings release, or any financing or M&A filing. It is a routine corporate announcement filed with the exchange, fitting the catch-all category of Regulatory Filings.
2026-05-29 Korean
단일판매ㆍ공급계약해지
Regulatory Filings Classification · 85% confidence The document is an announcement by KainosMed regarding the termination of a single supply contract (i-Ject auto injector) due to non‐payment by the counterparty. It provides contract details (amounts, dates, reasons) and references prior contract filings. It is not an annual or interim report, proxy or voting notice, dividend, board change, or financial results announcement, nor does it involve share issues or M&A. This is a miscellaneous regulatory event announcement, fitting the fallback "Regulatory Filings (RNS)" category.
2026-05-29 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean "분기보고서" (Quarterly Report) for the 10th term covering the period January 1, 2026 to March 31, 2026, containing detailed financial data, capital changes, stock schedules, business description, management changes, and other substantive content typical of an interim/quarterly financial report rather than a simple announcement or summary. This aligns with the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-15 Korean
[기재정정]단일판매ㆍ공급계약체결
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about a single sales and supply contract, including contract terms, counterparties, contract amounts, and amendments to the contract period. It does not contain financial statements or performance data but focuses on a specific contract agreement and its update. This fits the category of Capital/Financing Update (CAP), which includes updates on company fundraising, financing activities, or capital structure changes, including significant contracts that impact company revenue. The document length is short and it is not an announcement of a report publication, nor is it a regulatory certification or legal proceeding. Therefore, the best classification is CAP with high confidence.
2026-04-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is headed “정기주주총회 결과” (Results of the Annual General Meeting) and lists each agenda item with voting percentages, approval status, and director appointment details. It clearly provides the official outcomes of shareholder votes at the AGM. This matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-03-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.